Compare PXLW & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXLW | SCYX |
|---|---|---|
| Founded | 1997 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.3M | 44.4M |
| IPO Year | 2000 | 2014 |
| Metric | PXLW | SCYX |
|---|---|---|
| Price | $7.07 | $5.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $36.33 |
| AVG Volume (30 Days) | 24.6K | ★ 196.0K |
| Earning Date | 11-10-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | ★ 12.07 | N/A |
| Revenue | ★ $693,000.00 | $257,000.00 |
| Revenue This Year | $58.73 | N/A |
| Revenue Next Year | $63.64 | $906.41 |
| P/E Ratio | $0.57 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.84 | $0.57 |
| 52 Week High | $15.42 | $6.09 |
| Indicator | PXLW | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 52.75 |
| Support Level | $5.60 | $4.65 |
| Resistance Level | $7.16 | $5.56 |
| Average True Range (ATR) | 0.26 | 0.39 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 62.34 | 74.53 |
Pixelworks Inc is a provider of visual processing semiconductor and software solutions that enable consistently high-quality and authentic viewing experiences in a wide variety of applications. The company defines its key target markets as Mobile (smartphone and tablet), Home and Enterprise (projectors, personal video recorders (PVR), and over-the-air (OTA) streaming devices), and Cinema (creation, remastering, and delivery of digital video content). The company generates its revenue from two broad product markets: the Mobile market and the Home and Enterprise market. The majority of the revenue is earned in Japan.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.